$EW Cashflow Statement | Understand Stock

$EW

$91.78 +$0.96 (1.06%) Close

$EW Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
Non-cash operating lease cost
Stock-based compensation (Note 2 and Note 16)
Inventory write off (Note 2)
Impairment charges (Note 4)
Gain on sale of product groups (Note 5)
Deferred income taxes
Purchased in-process research and development (Note 4)
Change in fair value of contingent consideration liabilities (Note 13)
(Gain) loss on investments, net
Gain on remeasurement of previously held equity interest upon acquisition (Note 10)
Loss on impairment and intangible assets impairment charges (Note 11 and Note 9)
Other

Changes in operating assets and liabilities:
Accounts and other receivables, net
Inventories
Prepaid expenses and other current assets
Accounts payable and accrued liabilities
Intellectual property agreement accrual
Income taxes
Long-term prepaid royalties (Note 3)
Other
Net cash provided by operating activities
Cash flows from investing activities
Capital expenditures
Investments in unconsolidated entities (Note 8)
Purchases of held-to-maturity investments (Note 8)
Proceeds from sales and maturities of held-to-maturity investments (Note 8)
Purchases of available-for-sale investments (Note 8)
Proceeds from sales and maturities of available-for-sale investments (Note 8)
Acquisition (Note 8)
Business combinations, net of cash (Note 10)
Payments for acquisition options (Note 9)
Issuances of notes receivable
Collections of notes receivable
Investments in intangible assets
Payment for working capital adjustment and proceeds from sale of Critical Care (Note 5)
Proceeds from sale of non-core product group (Note 5)
Other
Net cash (used in) provided by investing activities

Cash flows from financing activities
Proceeds from issuance of debt
Payments on debt and finance lease obligations
Purchase of remaining noncontrolling interest in subsidiary (Note 9)
Purchases of treasury stock
Proceeds from stock plans
Other
Net cash used in financing activities
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash
Net (decrease) increase in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash at beginning of year
Cash, cash equivalents, and restricted cash at end of year (Note 6)

Comments